Related Experiment Video

Updated: May 7, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer

Ricardo Parrondo1, Alicia de Las Pozas, Teresita Reiner

  • 1Geriatric Research, Education, and Clinical Center and Research Service, Bruce W. Carter Veterans Affairs Medical Center , Miami, FL , USA.

Peerj
|September 24, 2013
PubMed

Insights

This study shows that combining ABT-737 with chemotherapy can overcome resistance in castration-resistant prostate cancer (CRPC) by targeting anti-apoptotic proteins. This approach enhances apoptosis and improves treatment efficacy for CRPC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Castration-resistant prostate cancer (CRPC) exhibits high levels of anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1), conferring resistance to apoptosis and poor prognosis.
  • Docetaxel, a first-line treatment for CRPC, offers limited survival benefit due to insufficient counteraction of these anti-apoptotic proteins.

Purpose of the Study:

  • To investigate the efficacy of ABT-737, a Bcl-2/Bcl-xL inhibitor, in sensitizing CRPC cells to chemotherapy.
  • To elucidate the mechanisms underlying ABT-737's effects on apoptosis in different CRPC cell lines.

Main Methods:

  • Utilized CRPC cell lines (LNCaP, PC3, DU145) with varying protein expression levels.
  • Administered ABT-737 in combination with docetaxel or ENMD-1198.
  • Performed gene knockdown (Bax, Bak, cyclin B1) and used specific inhibitors (purvalanol A) to analyze apoptotic pathways.

Main Results:

  • ABT-737 sensitized LNCaP and PC3 cells to docetaxel and ENMD-1198, enhancing caspase-dependent apoptosis.
  • DU145 cells, being Bax-null, showed resistance to ABT-737, indicating Bax's crucial role.
  • Docetaxel-induced phosphorylation of Bcl-2/Bcl-xL and Mcl-1 reduction were essential for ABT-737's sensitizing effect in PC3 cells.

Conclusions:

  • Targeting Bcl-2/Bcl-xL with ABT-737 and Mcl-1 with antimitotics can overcome anti-apoptotic protein-mediated resistance in Bax-expressing CRPC.
  • The combination therapy holds promise for improving CRPC treatment outcomes by re-sensitizing resistant cancer cells to apoptosis.
Keywords:
ABT-737AntimitoticApoptosisBcl-2 familyCyclin B1/Cdk1

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...